AMRN(6.67): Did anybody thought that it will be at these level?

LOL! Happens.

DSCO: Sheff is the PUDFA MARCH 6 th or dec. 6 th ?

Sheff how much are the chances of approval for RGEN

YMI- the CC was excellent . Definately gives you a closer perspective of jak inhibitors. As you point out Anaemia is the thing which will make it block buster and approvable in future . They have very strong patents. After people listens to CC they will realize what I am talking about . Anybody wanting to invest in YMI or is already invested should listen to Cc.

It's all about anemia and transfusion dependence, this is what separates this very specific Jak1/2 inhibitor (YMI) from others . I won't be surprised to see a partnership or buyout in near future .

Sheff , thanks for advise regarding analyst targets.

YMI CC at lazard- LINK: http://www.wsw.com/webcast/lz11/ym/

YMI- Meetings, including one today.


Calendar of Events

YM BioSciences will be participating or has participated in the following events. Please take advantage of these opportunities to make contact with the management of the company.


December 2011
53rd Annual Meeting of the American Society of Hematology
December 9-13, 2011
San Diego Convention Center
San Diego, CA

Poster presentation:
Poster #3849 "An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis"
Monday December 12, 2011 | 600 PM-8:00 PM PST
Location: Hall GH
Session #634: Myeloproliferative Syndromes: Poster III

YM Analyst / Investor Event
Tuesday December 13, 2011 | 6:30 AM-7:30 AM PST | listen to webcast
Grand Ballroom, Hotel Palomar; 1047 Fifth Av., San Diego CA

November 2011
Lazard Capital Markets 8th Annual Healthcare Conference
November 16, 2011 | 9:00 AM EST
Grand Ballroom, Annex A, The Pierre Hotel
New York, NY
Presenter: Nick Glover, President and CEO
listen to archived webcast

Annual and Special Meeting of Shareholders
November 22, 2011 | 4:00 PM EST
Boardrooms A & B, Offices of Norton Rose LLP
38th Floor, 200 Bay Street
Royal Bank Plaza, South Tower
Toronto, ON

INCY- Sinyan what a prediction!!

LOL!

Your msg was deleted but still made my day. LOL

When i was new to investing i got burned by these analysts price targets again and again, especially wedbush and RR.

Again, please, dont take it personally.

Congrates sheff!

Divide the wedbush and RR price targets by 4 and that will be real price, sorry if i offended any body.

Ha, ha, made my day!!!!!!

Agree!!!!!!!!!!!!!!!!!!!!

INCY_ trading starts, @ around 14 bucks. Should have been higher. i am not in to it . but price action is surprising to me.

Your post is not making any sense . I don't know what the heck r u talking about!!!!!!!!!!!!

Me too

Wow Ned serious , great , the best line is last one , I believe one day it will replace fillers.

Thanks , very good article , it seems many docs have started using it for acne scar also.

Sheff. i wish very good recovery from my heart. May god bless you.

YMI_ Absolutely $HEFF, anemia is the trumph card for YMI. I agree.

Ymi: CEO is eager to present the data at ash.

Nasdaq short interest is down from 3.2 m to 2.2 million in just last 15 days of October. Institutional holdings 59 percent. 76.5 m in cash . 4.4 m liabilities.

Very good catalyst play. Solid pick at Sheff station.

Thanks , Nice video.

NED serious : Very nice video, few more models like this and sales will pick up!

Thanks buddy, nice to see your boat back.

Ymi- agree wrinkle. My target is 2. 75

yes , you are right.

ASH is the mother of hem-onc conference and it has lot of weight. Interim data is good, very big market potential . recent multimillion dollar parternership of JAK1/2 inhibitors with big pharmas. >50 % institutional ownership, low short interest.

Good speculative play, IMO. Off course , sheffs backing does not hurts.

YMI_ Still dont know good job or bad job, time will tell, looks good this morning at least!

QCOR_ Ron, great pick. Our YMI is not doing bad this morning

THANKS KIPPER.

ymi_ DID NOT SELL SINGLE SHARE BECAUSE OF THIS BOARD AND MY GUT FEELING!!

November 2011
Lazard Capital Markets 8th Annual Healthcare Conference
November 16, 2011 | 9:00 AM EST
Grand Ballroom, Annex A, The Pierre Hotel
New York, NY
Presenter: Nick Glover, President and CEO

YMI- NEWS:

http://www.marketwatch.com/story/ym-biosciences-to-report-updated-phase-iii-data-for-cyt387-at-ash-2011-2011-11-07-12600

YMI CHART_ Awesooooooooome. Superb.

Thanks a lot.

YMI- sure, thanks. how about video chart BFR!

Bfr- ymi had great volume today. What does your chart says. Thanks

YMI_ Added here @ 1.86

Thanks would look in to it more closely.

Zgnx: very good DD. according to company website , if you go through the presentation in investor section , it says 261 million for zohydro and 66 million for their commercial product , migraine injection.

Am I missing something . I think phase three data will be good .

Analyst who do the offering always inflate the price, don't get me wrong . I am saying this as I have got burned severely by doing this in past . Good luck to you. Will definitely look in to it second half of 2012

Zgnx at what price they did offering? as I said company seems to be good , their lead catalyst with 261 million dollars potential ( hydrocodon ) is very far from approval , they are doing good progress with migraine injection sales .

Zgnx : I did some dd . They are a good company but it seems they have lots of problem with finance . They will have to raise money . Their lead product in development , hydro codon is far from approval , they need cash!